NASDAQ$ADAPY
Adaptimmune Therapeutics Plc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Adaptimmune reported financial results for Q1 2023 and provided a business update.
Adaptimmune reported revenue of $47.6 million and a net profit of $1.0 million for the first quarter ended March 31, 2023. The company completed submission of the clinical module of the afami-cel BLA and announced a strategic combination with TCR2.
- Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed engineered T-cell therapy for a solid tumor
- Adaptimmune and GSK agreed terms for transfer of PRAME and NY-ESO target programs; Adaptimmune will receive ~$37 million in upfront and milestone payments
- Announced strategic combination with TCR2 to create a preeminent cell therapy company for solid tumors; following closing of the transaction in Q2 2023, cash runway extended into early 2026
- Initiating the Phase 2 SURPASS-3 trial in combination with nivolumab for platinum resistant ovarian cancer
Headline financials
Revenue & EPS history
Adaptimmune · Revenue · Quarterly
$47.6M
Revenue by segment
Adaptimmune · $1.42M total across 1 segment · Q4 2021
- Development revenue$1.42M—100.0%
Forward guidance
The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech and payments under the Termination and Transfer Agreement with GSK, will fund the Company’s current operations into early 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
-3.0%
Avg return
Earnings day
-7.9%
Avg return
5 days after
-3.2%
Avg return
30 days after
37%
16 / 43 earnings
Positive
+26.5%
Q3 2022
Best reaction
-37.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.0% | -90.0% | — | |
| Q3 2025 | +0.0% | -90.0% | — | |
| Q2 2025 | +1.3% | -9.1% | -27.3% | |
| Q1 2025 | +4.7% | +0.7% | -7.9% | |
| Q4 2024 | -37.7% | -44.3% | -47.0% | |
| Q3 2024 | -25.5% | +12.5% | -1.9% | |
| Q2 2024 | +5.8% | +8.8% | +8.8% | |
| Q1 2024 | +4.3% | -4.3% | -12.2% | |
| Q4 2023 | +19.2% | +5.5% | -6.2% | |
| Q3 2023 | -8.2% | -20.6% | -8.6% | |
| Q2 2023 | -5.2% | -8.7% | -14.5% | |
| Q1 2023 | +2.2% | -1.5% | -27.4% | |
| Q4 2022 | -29.0% | -36.4% | -40.3% | |
| Q3 2022 | +26.5% | +51.2% | +6.0% | |
| Q2 2022 | +20.6% | +14.4% | +4.1% | |
| Q1 2022 | -8.8% | -17.5% | -0.6% | |
| Q4 2021 | -4.9% | +19.8% | +7.7% | |
| Q3 2021 | +0.0% | +0.7% | -34.6% | |
| Q2 2021 | +2.3% | +14.3% | +79.1% | |
| Q1 2021 | -6.6% | -6.7% | -7.4% | |
| Q4 2020 | -7.5% | -9.3% | -14.4% | |
| Q3 2020 | -1.7% | -7.9% | -15.7% | |
| Q2 2020 | -8.5% | -6.8% | -8.9% | |
| Q1 2020 | +2.4% | +13.9% | +118.9% | |
| Q4 2019 | +3.1% | -0.3% | -18.8% | |
| Q3 2019 | -18.2% | -25.6% | +1.8% | |
| Q2 2019 | -23.7% | -36.0% | -51.1% | |
| Q1 2019 | -6.9% | -9.1% | -18.1% | |
| Q4 2018 | -9.7% | -12.1% | -11.5% | |
| Q3 2018 | -6.7% | -13.3% | -19.4% | |
| Q2 2018 | -8.7% | -8.3% | +19.0% | |
| Q1 2018 | +2.6% | -0.5% | -1.2% | |
| Q4 2017 | +20.1% | +12.5% | +35.2% | |
| Q3 2017 | +8.8% | +8.8% | +7.9% | |
| Q2 2017 | +1.7% | +2.4% | +23.2% | |
| Q1 2017 | -3.0% | +4.1% | +0.6% | |
| Q3 2016 | +2.9% | +0.0% | -14.6% | |
| Q2 2016 | -7.2% | -12.6% | -16.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q4 2015 | -10.5% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q2 2015 | -0.8% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro